News
Phase III pivotal trial of M 001 vaccine fails to meet primary endpoints in influenza.- BiondVax Pharma
BiondVax Pharmaceuticals announced topline data from the Company's pivotal, phase III clinical trial of M 001 as a standalone universal flu vaccine candidate. Results did not demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints. The study's primary safety endpoint was met. The company has observed in seven previous studies that M 001 safely provoked an immune response to a broad range of flu strains, but ultimately this was not sufficient on a standalone basis to show protection.
Condition: Influenza
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins